EUVIMEDEUVIMED entdecken
Crossref

CON: Therapy for a Patient With Platinum–Resistant/Refractory Ovarian Cancer Should Not be Selected Based on Results of an In Vitro Extreme Drug Sensitivity/Resistance Assay

John Farley, Michael J. Birrer

Clinical Ovarian Cancer · 2011

DOI: 10.1016/j.cloc.2012.02.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Ovarian Cancer, 2011. Verfasst von John Farley und 1 weiteren Autor:innen. Die Arbeit nennt 29 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Farley, J., & Birrer, M. J. (2011). CON: Therapy for a Patient With Platinum–Resistant/Refractory Ovarian Cancer Should Not be Selected Based on Results of an In Vitro Extreme Drug Sensitivity/Resistance Assay. Clinical Ovarian Cancer. https://doi.org/10.1016/j.cloc.2012.02.003

Vancouver

Farley J, Birrer MJ. CON: Therapy for a Patient With Platinum–Resistant/Refractory Ovarian Cancer Should Not be Selected Based on Results of an In Vitro Extreme Drug Sensitivity/Resistance Assay. Clinical Ovarian Cancer. 2011. doi:10.1016/j.cloc.2012.02.003

BibTeX
@article{Farley2011,
  author = {Farley, John and Birrer, Michael J.},
  title = {CON: Therapy for a Patient With Platinum–Resistant/Refractory Ovarian Cancer Should Not be Selected Based on Results of an In Vitro Extreme Drug Sensitivity/Resistance Assay},
  journal = {Clinical Ovarian Cancer},
  year = {2011},
  doi = {10.1016/j.cloc.2012.02.003}
}
Kostenlos starten →